1. Home
  2. BUJA vs BOLD Comparison

BUJA vs BOLD Comparison

Compare BUJA & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BUJA
  • BOLD
  • Stock Information
  • Founded
  • BUJA 2022
  • BOLD 2018
  • Country
  • BUJA Malaysia
  • BOLD United States
  • Employees
  • BUJA N/A
  • BOLD N/A
  • Industry
  • BUJA Blank Checks
  • BOLD
  • Sector
  • BUJA Finance
  • BOLD
  • Exchange
  • BUJA Nasdaq
  • BOLD Nasdaq
  • Market Cap
  • BUJA N/A
  • BOLD 81.0M
  • IPO Year
  • BUJA 2023
  • BOLD 2024
  • Fundamental
  • Price
  • BUJA $10.96
  • BOLD $2.95
  • Analyst Decision
  • BUJA
  • BOLD Strong Buy
  • Analyst Count
  • BUJA 0
  • BOLD 3
  • Target Price
  • BUJA N/A
  • BOLD $23.00
  • AVG Volume (30 Days)
  • BUJA 2.7K
  • BOLD 57.8K
  • Earning Date
  • BUJA 01-01-0001
  • BOLD 11-11-2024
  • Dividend Yield
  • BUJA N/A
  • BOLD N/A
  • EPS Growth
  • BUJA N/A
  • BOLD N/A
  • EPS
  • BUJA 0.29
  • BOLD N/A
  • Revenue
  • BUJA N/A
  • BOLD N/A
  • Revenue This Year
  • BUJA N/A
  • BOLD N/A
  • Revenue Next Year
  • BUJA N/A
  • BOLD N/A
  • P/E Ratio
  • BUJA $37.13
  • BOLD N/A
  • Revenue Growth
  • BUJA N/A
  • BOLD N/A
  • 52 Week Low
  • BUJA $10.30
  • BOLD $2.82
  • 52 Week High
  • BUJA $12.18
  • BOLD $15.24
  • Technical
  • Relative Strength Index (RSI)
  • BUJA 67.66
  • BOLD N/A
  • Support Level
  • BUJA $10.85
  • BOLD N/A
  • Resistance Level
  • BUJA $10.85
  • BOLD N/A
  • Average True Range (ATR)
  • BUJA 0.00
  • BOLD 0.00
  • MACD
  • BUJA -0.00
  • BOLD 0.00
  • Stochastic Oscillator
  • BUJA 87.50
  • BOLD 0.00

About BUJA Bukit Jalil Global Acquisition 1 Ltd.

Bukit Jalil Global Acquisition 1 Ltd is a blank check company.

About BOLD Boundless Bio Inc. Common Stock

Boundless Bio Inc is a clinical-stage oncology company. It is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the significant unmet need in patients with oncogene amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in more than 14% of cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.

Share on Social Networks: